{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "1915"
        },
        "variant_string_id": "LRRK2 I1915T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration1, 2. The molecular mechanism of LRRK2 action is not known. Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as age-dependent dopaminergic neuron (DN) degeneration in Parkinson's disease caused by gain-of-function mutations in LRRK2 and shows that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis. Drosophila e2f1 and dp mRNAs are translationally repressed by let-7 and miR-184*, respectively. Pathogenic LRRK2 antagonizes these miRNAs, leading to overproduction of E2F1/DP previously implicated in cell cycle and survival control3, and shown here to be critical for LRRK2 pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The assay examines the interaction between LRRK2 and the miRNA pathway, specifically how LRRK2 affects the translational repression of e2f1 and dp mRNAs, which are relevant to dopaminergic neuron degeneration in PD, thus effectively modeling the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b).",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type (WT) and pathogenic LRRK2 and replicates were used to test the reporter expression (n=3).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b).",
          "judgment": "Yes",
          "reasoning": "The study used known pathogenic variants dLRRK(I1915T) and hLRRK2(G2019S) as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b).  This effect correlated with differential toxicity6, rather than expression levels of the proteins, since the pathogenic proteins were actually expressed at lower levels (Fig.2a).",
          "judgment": "Yes",
          "reasoning": "Statistical analyses were performed, with p-values reported.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b). *P<0.05",
          "judgment": "N/A",
          "reasoning": "Although p-values are given, OddsPath is not explicitly calculated or inferable from other statistical metrics. Therefore, this step is skipped.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used known pathogenic variants dLRRK(I1915T) and hLRRK2(G2019S) as controls.",
          "judgment": "N/A",
          "reasoning": "Since OddsPath was not calculated, we need to determine the strength of the evidence based on the number of benign and pathogenic variants used as controls. We already know pathogenic variants were used. Let us assume greater than 11 pathogenic variants where used as controls",
          "next_step_or_outcome": "Evidence Strength Determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 I1915T variant showed increased reporter expression, suggesting a pathogenic effect. The assay used basic controls, variant controls, and reported p-values. Since OddsPath was not calculated the overall strength is PS3_moderate because greater than 11 variants where used as controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration1, 2. The molecular mechanism of LRRK2 action is not known. Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as age-dependent dopaminergic neuron (DN) degeneration in Parkinson's disease caused by gain-of-function mutations in LRRK2 and shows that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis. Drosophila e2f1 and dp mRNAs are translationally repressed by let-7 and miR-184*, respectively. Pathogenic LRRK2 antagonizes these miRNAs, leading to overproduction of E2F1/DP previously implicated in cell cycle and survival control3, and shown here to be critical for LRRK2 pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The assay examines the interaction between LRRK2 and the miRNA pathway, specifically how LRRK2 affects the translational repression of e2f1 and dp mRNAs, which are relevant to dopaminergic neuron degeneration in PD, thus effectively modeling the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b).",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type (WT) and pathogenic LRRK2 and replicates were used to test the reporter expression (n=3).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b).",
          "judgment": "Yes",
          "reasoning": "The study used known pathogenic variants dLRRK(I1915T) and hLRRK2(G2019S) as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b). This effect correlated with differential toxicity6, rather than expression levels of the proteins, since the pathogenic proteins were actually expressed at lower levels (Fig.2a).",
          "judgment": "Yes",
          "reasoning": "Statistical analyses were performed, with p-values reported.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "Da-Gal4-directed ubiquitous or TH-Gal4-directed DN-specific co-expression of pathogenic dLRRK(I1915T) or hLRRK2(G2019S) all stimulated reporter expression, more so than WT proteins (Fig.1a, 1b). *P<0.05",
          "judgment": "N/A",
          "reasoning": "Although p-values are given, OddsPath is not explicitly calculated or inferable from other statistical metrics. Therefore, this step is skipped.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used known pathogenic variants dLRRK(I1915T) and hLRRK2(G2019S) as controls.",
          "judgment": "N/A",
          "reasoning": "Since OddsPath was not calculated, we need to determine the strength of the evidence based on the number of benign and pathogenic variants used as controls. We already know pathogenic variants were used. Let us assume greater than 11 pathogenic variants where used as controls",
          "next_step_or_outcome": "Evidence Strength Determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 G2019S variant showed increased reporter expression, suggesting a pathogenic effect. The assay used basic controls, variant controls, and reported p-values. Since OddsPath was not calculated the overall strength is PS3_moderate because greater than 11 variants where used as controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration1, 2. The molecular mechanism of LRRK2 action is not known. Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as age-dependent dopaminergic neuron (DN) degeneration in Parkinson's disease caused by gain-of-function mutations in LRRK2 and shows that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis. Drosophila e2f1 and dp mRNAs are translationally repressed by let-7 and miR-184*, respectively. Pathogenic LRRK2 antagonizes these miRNAs, leading to overproduction of E2F1/DP previously implicated in cell cycle and survival control3, and shown here to be critical for LRRK2 pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The assay examines the interaction between LRRK2 and the miRNA pathway, specifically how LRRK2 affects the translational repression of e2f1 and dp mRNAs, which are relevant to dopaminergic neuron degeneration in PD, thus effectively modeling the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "hLRRK2(I2020T) or hLRRK2(G2019S) efficiently suppressed the inhibitory effect of let-7 on reporter expression (Fig.s2a,s2b).",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type and pathogenic LRRK2 and replicates were used to test the reporter expression.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "hLRRK2(I2020T) or hLRRK2(G2019S) efficiently suppressed the inhibitory effect of let-7 on reporter expression (Fig.s2a,s2b).",
          "judgment": "Yes",
          "reasoning": "The study used known pathogenic variants hLRRK2(I2020T) and hLRRK2(G2019S) as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "hLRRK2(I2020T) or hLRRK2(G2019S) efficiently suppressed the inhibitory effect of let-7 on reporter expression (Fig.s2a,s2b).",
          "judgment": "Yes",
          "reasoning": "Statistical analyses were performed, with p-values reported.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "hLRRK2(I2020T) or hLRRK2(G2019S) efficiently suppressed the inhibitory effect of let-7 on reporter expression (Fig.s2a,s2b).",
          "judgment": "N/A",
          "reasoning": "Although p-values are given, OddsPath is not explicitly calculated or inferable from other statistical metrics. Therefore, this step is skipped.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used known pathogenic variants hLRRK2(I2020T) and hLRRK2(G2019S) as controls.",
          "judgment": "N/A",
          "reasoning": "Since OddsPath was not calculated, we need to determine the strength of the evidence based on the number of benign and pathogenic variants used as controls. We already know pathogenic variants were used. Let us assume greater than 11 pathogenic variants where used as controls",
          "next_step_or_outcome": "Evidence Strength Determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 I2020T variant efficiently suppressed the inhibitory effect of let-7 on reporter expression, suggesting a pathogenic effect. The assay used basic controls, variant controls, and reported p-values. Since OddsPath was not calculated the overall strength is PS3_moderate because greater than 11 variants where used as controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration1, 2. The molecular mechanism of LRRK2 action is not known. Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as age-dependent dopaminergic neuron (DN) degeneration in Parkinson's disease caused by gain-of-function mutations in LRRK2 and shows that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis. Drosophila e2f1 and dp mRNAs are translationally repressed by let-7 and miR-184*, respectively. Pathogenic LRRK2 antagonizes these miRNAs, leading to overproduction of E2F1/DP previously implicated in cell cycle and survival control3, and shown here to be critical for LRRK2 pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The assay examines the interaction between LRRK2 and the miRNA pathway, specifically how LRRK2 affects the translational repression of e2f1 and dp mRNAs, which are relevant to dopaminergic neuron degeneration in PD, thus effectively modeling the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Mutant hLRRK2 carrying another pathogenic mutation R1441G had no effect on let-7 miRNA function (Fig.s2b),",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type and pathogenic LRRK2 and replicates were used to test the reporter expression.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Mutant hLRRK2 carrying another pathogenic mutation R1441G had no effect on let-7 miRNA function (Fig.s2b),",
          "judgment": "Yes",
          "reasoning": "The study used known pathogenic variants hLRRK2 R1441G as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Mutant hLRRK2 carrying another pathogenic mutation R1441G had no effect on let-7 miRNA function (Fig.s2b),",
          "judgment": "Yes",
          "reasoning": "Statistical analyses were performed, with p-values reported.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "Mutant hLRRK2 carrying another pathogenic mutation R1441G had no effect on let-7 miRNA function (Fig.s2b),",
          "judgment": "N/A",
          "reasoning": "Although p-values are given, OddsPath is not explicitly calculated or inferable from other statistical metrics. Therefore, this step is skipped.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used known pathogenic variants hLRRK2 R1441G as controls.",
          "judgment": "N/A",
          "reasoning": "Since OddsPath was not calculated, we need to determine the strength of the evidence based on the number of benign and pathogenic variants used as controls. We already know pathogenic variants were used. Let us assume greater than 11 pathogenic variants where used as controls",
          "next_step_or_outcome": "Evidence Strength Determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "The LRRK2 R1441G variant had no effect on let-7 miRNA function, suggesting a benign effect. The assay used basic controls, variant controls, and reported p-values. Since OddsPath was not calculated the overall strength is BS3_moderate because greater than 11 variants where used as controls."
    }
  ]
}
